ABATACEPT 250 MG INJECTION
ORENCIA (abatacept) is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is produced by recombinant DNA technology in a mammalian cell expression system. The apparent molecular weight of abatacept is 92 kilodaltons. ORENCIA lyophilized powder for intravenous infusion is supplied as a sterile, white,preservative-free, lyophilized powder for intravenous administration.
* 250 mg lyophilized powder in a single-use vial for intravenous infusion, * 125 mg/mL solution in a single-dose prefilled syringe.
Please click here - https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125118s171lbl.pdf
ORENCIA is a selective T cell costimulation modulator indicated for: Adult Rheumatoid Arthritis (RA), moderately to severely active RA in adults. ORENCIA may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists.
Juvenile Idiopathic Arthritis: moderately to severely active polyarticular juvenile idiopathic arthritis in pediatric patients 6 years of age and older. ORENCIA may be used as monotherapy or concomitantly with methotrexate Important
Important Limitations of Use , should not be given concomitantly with TNF antagonists
